RxDoctor Payments Data

Aju George, MD

Internal Medicine · Orlando, FLNPI 1689617698

Payments from drug & device makers

$1,099in general payments, 2019–2025

Across 44 payments — averaging $24.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$192
  • GSK$160
  • Bayer$147
  • Pfizer$146
  • Boehringer Ingelheim$105
  • Lundbeck LLC$102
  • plus $247 from 5 others

What the payments were for

  • Food & beverage$1,099100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca7$192
GSK9$160
Bayer6$147
Pfizer2$146
Boehringer Ingelheim4$105
Lundbeck LLC4$102
Novo Nordisk4$87
Abbott4$87
Lilly USA, LLC2$44
Portola Pharmaceuticals, LLC1$15
CMP Pharma, Inc.1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,099 in reported general payments places this provider in the 70th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$58,500
Medicare patients
140
Services billed
610

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban99$105,603
FarxigaDapagliflozin Propanediol77$70,772
JardianceEmpagliflozin31$45,987
Synjardy XrEmpagliflozin/Metformin Hcl56$44,026
MounjaroTirzepatide15$33,593
JanuviaSitagliptin Phosphate19$32,000
Trelegy ElliptaFluticasone/Umeclidin/Vilanter31$29,701
OzempicSemaglutide17$18,719
RexultiBrexpiprazole12$17,756
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog19$15,240
XareltoRivaroxaban12$14,838
Novolog FlexpenInsulin Aspart52$12,249
Breo ElliptaFluticasone/Vilanterol21$9,099
Advair HfaFluticasone Propion/Salmeterol24$8,829
LinzessLinaclotide15$7,825

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$146$105,60399 claims
Boehringer IngelheimJardiance, Synjardy Xr$105$90,01387 claims
AstraZenecaFarxiga$192$70,77277 claims
GSKTrelegy Ellipta, Breo Ellipta$160$38,80052 claims
Lilly USA, LLCMounjaro$44$33,59315 claims
Novo NordiskOzempic$87$18,71917 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Orlando

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →